Literature DB >> 1909351

Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.

J A Dent1, M Galbusera, Z M Ruggeri.   

Abstract

In this report we demonstrate that proteolytic cleavage of the constituent subunit is one of the causes determining the heterogeneous size distribution of plasma von Willebrand factor (vWf) multimers. As shown by two-dimensional nonreduced/reduced agarose/polyacrylamide gel electrophoresis, the structure of circulating vWf molecules may deviate from that represented by assemblage of a variable number of identical subunits. Indeed, even though the largest multimers in normal plasma appear to be composed predominantly of intact 225-kD subunits, those of intermediate and smaller size contain also 189-, 176-, and 140-kD proteolytic fragments. Different subunit composition patterns are repeated regularly in multimers of increasing molecular mass, yielding series of bands with similar structure. One of these series consists of molecules without evidence of proteolytic fragmentation, and its smallest member appears to be a dimer of 225-kD subunits. Type IIA von Willebrand disease, characterized by absence of the largest multimers, displays a pattern wherein the fragments of 176 and 140 kD are relatively increased, that of 189 kD is markedly decreased or absent, but the composition of individual multimers is otherwise similar to that of species seen also in normal plasma. In contrast to those in the circulation, all normal platelet vWf multimers contain only intact subunit. These results suggest that proteolytic cleavage of plasma vWf subunits occurs after release from cellular sites, whereas platelet vWf stored in alpha-granules is protected from proteolysis. These findings provide information that may be relevant for understanding the normal processing of vWf multimers and for elucidating the pathogenesis of some of the congenital and acquired structural abnormalities of this molecule.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909351      PMCID: PMC295461          DOI: 10.1172/JCI115376

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.

Authors:  D Ginsburg; B A Konkle; J C Gill; R R Montgomery; P L Bockenstedt; T A Johnson; A Y Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

2.  Human von Willebrand factor: a multivalent protein composed of identical subunits.

Authors:  M W Chopek; J P Girma; K Fujikawa; E W Davie; K Titani
Journal:  Biochemistry       Date:  1986-06-03       Impact factor: 3.162

3.  Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size.

Authors:  A B Federici; R Bader; S Pagani; M L Colibretti; L De Marco; P M Mannucci
Journal:  Br J Haematol       Date:  1989-09       Impact factor: 6.998

4.  Topology and order of formation of interchain disulfide bonds in von Willebrand factor.

Authors:  D D Wagner; S O Lawrence; B M Ohlsson-Wilhelm; P J Fay; V J Marder
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

5.  Amino acid sequence of human von Willebrand factor.

Authors:  K Titani; S Kumar; K Takio; L H Ericsson; R D Wade; K Ashida; K A Walsh; M W Chopek; J E Sadler; K Fujikawa
Journal:  Biochemistry       Date:  1986-06-03       Impact factor: 3.162

Review 6.  von Willebrand factor and von Willebrand disease.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

7.  von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib.

Authors:  Y Fujimura; K Titani; L Z Holland; S R Russell; J R Roberts; J H Elder; Z M Ruggeri; T S Zimmerman
Journal:  J Biol Chem       Date:  1986-01-05       Impact factor: 5.157

8.  Substructure of human von Willebrand factor.

Authors:  W E Fowler; L J Fretto; K K Hamilton; H P Erickson; P A McKee
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  A variant of type II von Willebrand disease with an abnormal triplet structure and discordant effects of protease inhibitors on plasma and platelet von Willebrand factor structure.

Authors:  H R Gralnick; S B Williams; L P McKeown; P Maisonneuve; C Jenneau; Y Sultan
Journal:  Am J Hematol       Date:  1987-03       Impact factor: 10.047

10.  Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.

Authors:  S D Berkowitz; J Dent; J Roberts; Y Fujimura; E F Plow; K Titani; Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

View more
  31 in total

Review 1.  Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  S L Allford; S J Machin
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

2.  von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.

Authors:  Anil K Chauhan; Janka Kisucka; Colin B Lamb; Wolfgang Bergmeier; Denisa D Wagner
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

3.  Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow.

Authors:  Zhenyin Tao; Yongtao Wang; Huiwei Choi; Aubrey Bernardo; Kenji Nishio; J Evan Sadler; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

4.  In vivo imaging analysis of the interaction between unusually large von Willebrand factor multimers and platelets on the surface of vascular wall.

Authors:  Miroslaw Rybaltowski; Yuko Suzuki; Hideo Mogami; Iwona Chlebinska; Tomasz Brzoska; Aki Tanaka; Fumiaki Banno; Toshiyuki Miyata; Tetsumei Urano
Journal:  Pflugers Arch       Date:  2011-04-15       Impact factor: 3.657

Review 5.  Role of von Willebrand factor in the haemostasis.

Authors:  Flora Peyvandi; Isabella Garagiola; Luciano Baronciani
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

Review 6.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 7.  Thrombotic microangiopathies: multimers, metalloprotease, and beyond.

Authors:  Joel Moake
Journal:  Clin Transl Sci       Date:  2009-10       Impact factor: 4.689

Review 8.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

9.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

10.  Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.

Authors:  Almudena Pérez-Rodríguez; Aranzazu García-Rivero; Esther Lourés; Maria Fernanda López-Fernández; Angela Rodríguez-Trillo; Javier Batlle
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.